Latizolil

Latanoprost, the active ingredient in Latizolil, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is used to treat open-angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latizolil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latizolil is a prostaglandin analog indicated for conditions that require reduction of intraocular pressure.

Open-angle glaucoma: reduces intraocular pressure to prevent optic nerve damage. Ocular hypertension: lowers elevated eye pressure to reduce risk of progression to glaucoma. Pseudoexfoliative glaucoma: helps control intraocular pressure in this secondary open‑angle form.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length, thickness, or number. - Darkening of the iris (especially in mixed‑color eyes). - Eye irritation or foreign‑body sensation. - Blurred vision, especially after instillation. - Mild ocular discomfort or itching.

Serious or Rare Side Effects: - Uveitis or intraocular inflammation. - Cystoid macular edema leading to vision changes. - Severe allergic reaction (e.g., swelling, rash). - Persistent eye pain or photophobia. - Sudden loss of vision. - Corneal edema or endothelial damage.

Before using Latizolil, consider the following safety measures.

Pregnancy: safety unknown; avoid use unless benefits outweigh risks. Breastfeeding: insufficient data; caution advised. Active ocular infection: contraindicated until infection resolves. Monitor intraocular pressure: ensure adequate pressure reduction without causing hypotony. Contact lens wearers: remove lenses before instillation and wait before reinserting. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy. - Concurrent prostaglandin analogs: risk of excessive IOP lowering and hypotony. - Systemic carbonic anhydrase inhibitors: may increase ocular side‑effect risk.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Alpha‑agonist eye drops: may require IOP monitoring for synergistic effect. - Systemic corticosteroids: can reduce latanoprost’s pressure‑lowering action.